CommercialCoverageLow impact
Treatment of Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis
Blue Cross & Blue Shield of Mississippi·MS · Cardiology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their policy for transthyretin-mediated amyloidosis (ATTR-CM) treatment, adding two new medications (Amvuttra and Attruby) but designating them as not medically necessary since formulary alternatives exist. The policy also revised diagnostic confirmation requirements to include tissue biopsy, nuclear scintigraphy, or genetic testing.
Action Required
Immediately: Billing team should note that for BCBS Mississippi plans, only Vyndaqel and Vyndamax are approved for ATTR-CM treatment with prior authorization. Claims for Amvuttra (vutrisiran) and Attruby (acoramidis) will likely be denied as not medically necessary. Ensure prior auth requests include confirmation of diagnosis via tissue biopsy, nuclear scintigraphy, or TTR genetic testing.